Next Generation


From its platform, the company has developed the promising pipeline-in-a-drug candidate asunercept. It targets the CD95 dependent signaling pathways in cancer and it plays a role in improving the immune response against cancer and viral infections. There is also a strong scientific rationale that asunercept can be developed in dermatology and ophthalmology.


>> More about COVID-19
>> More about immuno-oncology


Clinical Development in Three Indications

Our lead immunotherapy candidate asunercept is in clinical development for the treatment of solid tumors, malignant hematological diseases, and COVID-19. It has shown significant improvements in progression-free survival and quality of life as well as a positive trend in overall survival in a controlled phase II proof-of-concept trial in recurrent glioblastoma. In a phase I trial in myelodysplastic syndromes (MDS), treatment with asunercept led to a decrease in transfusion frequency in 40 percent of patients during the duration of the trial.



The Apogenix team has created the HERA-ligand technology platform for the development of novel receptor agonists that target different TNFSF-dependent signaling pathways, which play a crucial role in the regulation of the immune response. These fusion proteins offer clear advantages over other biologics such as antibodies and have the potential for broad application in oncology. The further development of drug candidates from the HERA-platform is  currently on hold.



June 1, 2023
Apogenix’ new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model

March 27, 2023
Apogenix’ Partner CANbridge Announces 67 % Five-Year Overall Survival Rate Compared to 8.2 % in Institutional Database With Asunercept Plus SOC in Newly Diagnosed Glioblastoma Multiforme Patients